Gene Therapy with HSV1-sr39TK/GCV Exhibits a Stronger Therapeutic Efficacy Than HSV1-TK/GCV in Rat C6 Glioma Cells
Figure 6
Representative microPET images before ganciclovir (GCV) administration ((a) and (c)) and by the end of experiment (10 days after GCV administration) ((b) and (d)). Arrow represented control C6 xenograft tumor and triangle represented C6-TK xenograft tumor in (a) and (b) and C6-sr39TK xenograft tumor in (c) and (d), respectively. SNK analysis revealed that the ratio of radioactivity (tumor/muscle) in C6-sr39TK and C6-TK group was significantly lower than the control group (), but not between them ().
